Palvella Therapeutics (NASDAQ:PVLA) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $38.00 price target on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2029 earnings at ($0.69) EPS.

Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $13.25 on Friday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $22.32. The stock has a market capitalization of $17.49 million, a PE ratio of -1.10 and a beta of 0.61.

Insider Activity at Palvella Therapeutics

In other news, Director George M. Jenkins acquired 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the transaction, the director now directly owns 180,671 shares in the company, valued at $2,336,076.03. This trade represents a 2.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.39% of the stock is currently owned by insiders.